JPH02121909A - Cosmetic for pimple - Google Patents
Cosmetic for pimpleInfo
- Publication number
- JPH02121909A JPH02121909A JP27431388A JP27431388A JPH02121909A JP H02121909 A JPH02121909 A JP H02121909A JP 27431388 A JP27431388 A JP 27431388A JP 27431388 A JP27431388 A JP 27431388A JP H02121909 A JPH02121909 A JP H02121909A
- Authority
- JP
- Japan
- Prior art keywords
- egg yolk
- skin
- acne
- pimple
- cosmetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010000496 acne Diseases 0.000 title claims abstract description 42
- 239000002537 cosmetic Substances 0.000 title claims abstract description 10
- 210000002969 egg yolk Anatomy 0.000 claims abstract description 29
- 235000013345 egg yolk Nutrition 0.000 claims abstract description 27
- 108010000912 Egg Proteins Proteins 0.000 claims abstract description 25
- 102000002322 Egg Proteins Human genes 0.000 claims abstract description 25
- 241000186427 Cutibacterium acnes Species 0.000 claims abstract description 22
- 229920001284 acidic polysaccharide Polymers 0.000 claims abstract description 20
- 150000004805 acidic polysaccharides Chemical class 0.000 claims abstract description 19
- 241000894006 Bacteria Species 0.000 claims abstract description 10
- 235000013601 eggs Nutrition 0.000 claims abstract description 10
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 35
- 241000287828 Gallus gallus Species 0.000 claims description 17
- 235000013330 chicken meat Nutrition 0.000 claims description 17
- 229940055019 propionibacterium acne Drugs 0.000 claims description 3
- 230000003053 immunization Effects 0.000 abstract description 17
- 210000004027 cell Anatomy 0.000 abstract description 13
- 239000000203 mixture Substances 0.000 abstract description 8
- 241000186429 Propionibacterium Species 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 230000000638 stimulation Effects 0.000 abstract 2
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 230000001580 bacterial effect Effects 0.000 description 14
- 238000002649 immunization Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 208000020154 Acnes Diseases 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000007933 dermal patch Substances 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 239000002884 skin cream Substances 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 235000011130 ammonium sulphate Nutrition 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- -1 etc. Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 210000002374 sebum Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007621 bhi medium Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229940116333 ethyl lactate Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 210000002976 pectoralis muscle Anatomy 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- VXYADVIJALMOEQ-UHFFFAOYSA-K tris(lactato)aluminium Chemical compound CC(O)C(=O)O[Al](OC(=O)C(C)O)OC(=O)C(C)O VXYADVIJALMOEQ-UHFFFAOYSA-K 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
【発明の詳細な説明】
(産業上の利用分野)
本発明は、プロピオニバクテリウム・アクネス(以下P
、アクネスと略記する)が菌体外に産生ずる酸性多糖を
免疫した鶏の卵より調製された卵黄抗体を含有すること
を特徴とする新規なにきび用化粧料に関する。Detailed Description of the Invention (Industrial Field of Application) The present invention is directed to Propionibacterium acnes (hereinafter referred to as P. acnes).
The present invention relates to a novel cosmetic for acne, characterized by containing an egg yolk antibody prepared from eggs of chickens immunized with acidic polysaccharides produced extracellularly by bacteria.
(従来の技術及び発明が解決しようとする課!!II)
にきびは、皮膚の体裁を醜くし、かつしばしば厄介な症
状を伴い、皮脂腺に冨む皮膚の成る領域、特に顔、頚、
背に発生する。にきびの発生原因は、主として、■皮脂
の過剰な分泌、■毛包脂肪系排出管の閉塞、■し包脂1
1.9 W内のプロピオニバクテリウム属の細菌(主と
してP、アクネス)の存在などである。これらの発生因
子によって、特徴的なにきびの面心、丘疹、纏庖等の症
状が現れる。(The problem to be solved by the conventional technology and invention!! II)
Acne is an unsightly and often bothersome condition that affects areas of the skin that are rich in sebaceous glands, especially the face, neck, and skin.
Occurs on the back. The main causes of acne are ■ excessive secretion of sebum, ■ blockage of the hair follicle fatty drainage tube, and ■ sebum 1.
1.9 The presence of bacteria of the genus Propionibacterium (mainly P. acnes) in W. Depending on these factors, characteristic acne symptoms such as pimples, papules, and pimples appear.
現在、主流を占めているにきびのY・防法、処置法或い
は治療法は、■過剰な皮脂の分泌をj印判すること、■
毛包の閉塞を除去すること、■細菌の増殖を抑制し、更
には殺菌処理を施すこと、■炎症作用をllTl ;i
、IIすること等が挙げられる。Currently, the main methods of preventing, treating, or treating acne are: ■ Controlling excessive sebum secretion; ■
Remove blockages in hair follicles; ■ Inhibit bacterial growth and perform sterilization; ■ Prevent inflammatory effects;
, II, etc.
抗体を応用した組成物としては、抗体及びこれを有効成
分とするスプレー剤(特開昭621754213)、!
・すないしウシ抗体を用いたlI+fiII物の受動免
疫化方法及びそのための組成物(特開昭60−2.i’
4862 B )があるが、単にIm菌単独をニワトリ
等の鳥類やウシ等のtl+!i乳類に免疫しても、得ら
れるiに体の細菌に対する制菌効果等の直接的な効果は
期待出来ず、P、アクネス等により生ずるニキビの炎症
には必ずしも効果的ではないのが現状である。Examples of compositions using antibodies include antibodies and sprays containing the same as active ingredients (Japanese Patent Application Laid-Open No. 621754213).
・Method for passive immunization of lI+fiII using bovine antibodies and compositions therefor (Japanese Patent Application Laid-open No. 60-2.i'
4862 B), but Im bacteria alone can be isolated from birds such as chickens, cows, etc. tl+! Even if you immunize mammals, you cannot expect the resulting i to have a direct effect such as an antibacterial effect on bacteria in the body, and the current situation is that it is not necessarily effective against acne inflammation caused by P. acnes, etc. It is.
本発明は、皮膚刺激性が無く、にきびの143療に有効
なる作用を有する全く新しいにきび用化粧料を提供する
ことを目的としている。The object of the present invention is to provide a completely new cosmetic for acne that is non-irritating to the skin and has an effective treatment for acne.
(課題を解決するための手段)
本発明は、皮膚の常在菌であるプロピオニバクテリウム
・アクネスが菌体外に産生ずる酸性多糖を免疫した鶏が
産生ずる卵より調製された卵黄抗体を含有することを特
徴とするにきび用化粧料である。(Means for Solving the Problems) The present invention uses egg yolk antibodies prepared from eggs produced by chickens immunized with acidic polysaccharides produced extracellularly by Propionibacterium acnes, which is a resident bacteria on the skin. A cosmetic for acne characterized by containing:
本発明に係る卵黄抗体は、P、アクネスが菌体外に産生
ずる酸性多糖を免疫した鶏が産生ずる卵より容易に調製
される。The egg yolk antibody according to the present invention is easily prepared from eggs produced by chickens immunized with the acidic polysaccharide produced extracellularly by P. acnes.
ここで、本発明に使用するP、アクネスは、通常の嫌気
性菌の培養に使用されるプレイン・ハート・インフュー
ジョン培地(BHI培地)などの液体培地を用い、嫌気
的に37℃で3〜lO日間培養することで培養を行い、
遠心分離することにより容易に得られる。Here, P acnes used in the present invention is grown anaerobically at 37°C for 3 to 30 minutes using a liquid medium such as plain heart infusion medium (BHI medium), which is commonly used for culturing anaerobic bacteria. Culture is carried out by culturing for 10 days,
Easily obtained by centrifugation.
P、アクネスが菌体外に産生ずる酸性多糖は、P、アク
ネスの培養濾液より、硫酸アンモニウム沈澱、アルコー
ル沈澱、限外濾過等の操作により濃縮、回収される。こ
の酸性多糖成分は更に、セファデックスG−100,セ
ファロースCL−6[3等によるカラムクロマトグラフ
ィーを行い、免疫−次拡散法により、抗P、アクネス・
ウナギ血清抗体に対して陽性反応を示す分画を集めるこ
とで精製が可能である。得られた酸性多糖は、集めて蒸
留水に対して透析を行い、凍結乾燥により、保存が可能
である。また、そのまま凍結保存することも可能である
。The acidic polysaccharide produced by P. acnes outside the bacterial cells is concentrated and recovered from the culture filtrate of P. acnes by operations such as ammonium sulfate precipitation, alcohol precipitation, and ultrafiltration. This acidic polysaccharide component was further subjected to column chromatography using Sephadex G-100, Sepharose CL-6 [3, etc., and was analyzed by immuno-diffusion method to obtain anti-P, acnes, etc.
Purification is possible by collecting fractions that show a positive reaction to eel serum antibodies. The obtained acidic polysaccharide can be stored by collecting, dialysis against distilled water, and freeze-drying. It is also possible to freeze and preserve it as it is.
免疫操作に用いる鶏としては、特に制限はないが、抗体
の量産性という点からは、白色レグホンなどの卵用種を
用いるとよい。There are no particular restrictions on the chicken used for the immunization procedure, but from the standpoint of mass production of antibodies, egg-producing chickens such as white leghorn are preferably used.
また、免疫方法としては、皮下注射、腹腔内注射、筋肉
注射などによる通常の方法や、点鼻、点IJ?などの方
法によって行うことができる。In addition, immunization methods include conventional methods such as subcutaneous injection, intraperitoneal injection, and intramuscular injection, as well as nasal drops, IJ injections, etc. This can be done by methods such as.
更に、抗原の投与量は、所望の抗体値が得られ、かつ鶏
に対して悪影響を与えない量を適宜選択して用いればよ
い。また、必要に応じて完全フロインドアジュバント、
不完全フロインドアジュバントなどのアジュバントと併
用してもよい。Furthermore, the amount of antigen to be administered may be appropriately selected so that the desired antibody value is obtained and does not have an adverse effect on the chickens. In addition, complete Freund's adjuvant, if necessary.
It may be used in combination with an adjuvant such as incomplete Freund's adjuvant.
免疫後に、約2週間の間隔で抗体価をエンザイムイムノ
アッセイ、ラジオイムノアッセイ等の方法により測定し
、推移を追跡する。通常、初回免疫から数週間で投与抗
原に対して特異的に反応する抗体が卵(卵黄)中に得ら
れるが、通常約3ケ月間で抗体としての効果を発揮する
のに充分な高い抗体価をもつ抗体が得られる。なお、免
疫後、抗体価の減少が認められる場合、適当な間隔で適
宜追加免疫することにより抗体価を高めることができる
。After immunization, the antibody titer is measured at intervals of about two weeks by methods such as enzyme immunoassay and radioimmunoassay to track the progress. Usually, antibodies that specifically react with the administered antigen are obtained in eggs (egg yolks) within a few weeks after the first immunization, but the antibody titer is usually high enough to exert its effect as an antibody within about 3 months. Antibodies with this can be obtained. If a decrease in antibody titer is observed after immunization, the antibody titer can be increased by appropriately administering booster immunizations at appropriate intervals.
本発明に係る卵黄抗体は、この、免疫した鶏が産生ずる
卵の卵黄より、クロロホルムを添加し、振とう、撹拌、
遠心分離を行うことにより脂質を除去した後の上清の水
溶液より得られ、蒸留水に対して透析後、濾過滅菌、凍
結乾燥等の操作により保存が可能である。得られた卵黄
抗体は白色から淡黄色を呈し、主として免疫グロブリン
(y −リベチン)からなるタンパク質成分であるが、
その他β−1α−リヘチン、オボアルブミンなどのタン
パク質成分も含有している。The egg yolk antibody according to the present invention is prepared by adding chloroform to the yolk of eggs produced by immunized chickens, shaking, stirring,
It is obtained from an aqueous supernatant solution after lipids are removed by centrifugation, and can be preserved by dialysis against distilled water, sterilization by filtration, freeze-drying, and other operations. The obtained egg yolk antibody exhibits a white to pale yellow color and is a protein component mainly composed of immunoglobulin (y-livetin).
It also contains other protein components such as β-1α-lihetin and ovalbumin.
本発明に係る卵黄抗体は、未精製の状態でも使用するこ
とができるが、卵黄中に含まれる免疫グ「1プリンを抽
出・分離することによって更に高い抗体価が得られる。Although the egg yolk antibody according to the present invention can be used in an unpurified state, an even higher antibody titer can be obtained by extracting and separating the immune protein "1 purine" contained in the egg yolk.
抽出・分離方法としては、硫酸アンモニウム、硫酸ナト
リウム等の塩類、またはデキストラン硫酸やポリエチレ
ングリコール等の高分子化合物を用いた沈澱法や、DB
八へセルロース等を用いるイオン交換クロマ1−グラフ
ィーやセファロース類、セファデックス類等のゲル濾過
剤を用いるゲル濾過クロマトグラフィー等によっても更
に精製が可能である。その他、通常用いられている免疫
グロブリンを抽出・分離できる各種の方法等が利用でき
る。Extraction and separation methods include precipitation methods using salts such as ammonium sulfate and sodium sulfate, or polymeric compounds such as dextran sulfate and polyethylene glycol, and DB
Further purification is also possible by ion exchange chromatography using cellulose or the like, gel filtration chromatography using a gel filtration agent such as Sepharose or Sephadex. In addition, various commonly used methods for extracting and separating immunoglobulins can be used.
本分画は、水溶性であり、最高で10重間%迄溶解可能
である。その他アルコールを含む水?8 Hにも溶解が
可能である。This fraction is water soluble and can dissolve up to 10% by weight. Other water containing alcohol? 8H can also be dissolved.
本発明に係る卵黄抗体のP、アクネスに対する作用メカ
ニズムは次の如くに考えられる。P、アクネスが菌体外
に産生ずる酸性多糖をニワトリに免疫して得られる卵黄
抗体は、P、アクネスの酸性多糖の産生を抑制し、菌体
の表面に特異的に結合して菌の活動や増殖を抑制する。The mechanism of action of the egg yolk antibody according to the present invention against P acnes is thought to be as follows. The egg yolk antibody obtained by immunizing chickens with the acidic polysaccharide produced by P. acnes outside the bacterial body inhibits the production of the acidic polysaccharide of P. acnes, binds specifically to the surface of the bacterial cell, and inhibits bacterial activity. and inhibits proliferation.
従って、P。Therefore, P.
アクネスが菌体外に産生し、皮膚内での炎症反応を増強
すると考えられている酸性多糖あるいはリパーゼ、酸性
ホスファターゼ、ヒアルロニダーゼ、プロテアーゼ、ニ
ューラミニダーゼなどの産生も結果的に抑制され、その
炎症の惹起能力を阻害或いは低下さ−することにより、
優れたにきび治療効果を発揮するものと推察される。As a result, the production of acidic polysaccharides, lipase, acid phosphatase, hyaluronidase, protease, neuraminidase, etc., which are produced outside the bacterial cells of P. acnes and are thought to enhance the inflammatory response within the skin, is suppressed, and the inflammation is suppressed. By inhibiting or reducing the ability to induce
It is presumed that it exhibits excellent acne treatment effects.
本発明に係る卵黄抗体の配合量はにきび用化粧$4 (
Mi成物)の総量を基準として大略0.0001〜0.
5重量%(以下wt%と略記する)の範囲である。ここ
で、卵黄抗体の配合量は、0.0001wL%未満では
効果が充分に達成されず、0.5wt%を超えてもその
増加分に見合った効果の向−Lは望めない。The blending amount of the egg yolk antibody according to the present invention is $4 for acne makeup (
Approximately 0.0001 to 0.000% based on the total amount of Mi products).
The range is 5% by weight (hereinafter abbreviated as wt%). Here, if the amount of the egg yolk antibody blended is less than 0.0001 wL%, the effect will not be sufficiently achieved, and even if it exceeds 0.5 wt%, an increase in the effect commensurate with the increased amount cannot be expected.
更に、本発明のニキビ用化粧料は、通常使用される角質
溶解作用を有する成分として、レヅルシン、イオウ、サ
リチル酸、尿素、イソプロピルメチルフェノール等、殺
菌作用を存する成分として、グルコン酸りロルヘニ1ソ
ジン、塩酸クロルヘキンジシ、塩化ヘンザルコニウム、
塩化ベンザ1ニウム、その他の成分として、グリチルリ
チン、グリチルレチン酸、アラントイン、酸化亜鉛、硫
酸亜鉛、乳酸アルミニウム、乳酸エチル、エストラジオ
、−ル、カンフル、ビオチン等を同時に配合することも
可能であり、その場合、より一層効果の増強が期待でき
る。また、その他の添加剤である抗酸化剤、香料、色素
、各種ビタミン類等を本発明の「1的を達成する範囲で
適宜調製し配合することが可能である。Furthermore, the cosmetic for acne of the present invention includes commonly used ingredients having a keratolytic effect such as redulucin, sulfur, salicylic acid, urea, isopropyl methylphenol, etc., and ingredients having a bactericidal effect such as gluconate lorcheni-1 sodine, Chlorhequine hydrochloride, Henzalkonium chloride,
Benzanium chloride and other ingredients such as glycyrrhizin, glycyrrhetinic acid, allantoin, zinc oxide, zinc sulfate, aluminum lactate, ethyl lactate, estradiol, camphor, biotin, etc. can be combined at the same time. In this case, further enhancement of the effect can be expected. Further, other additives such as antioxidants, fragrances, pigments, various vitamins, etc. can be appropriately prepared and blended within the range that achieves the first objective of the present invention.
本発明のにきび用化粧料は、ローン9ン類、乳液類、ク
リーム類、ゲル状物、スティ、り状物等の剤型に通常の
方法により調製することが可能である。The cosmetic for acne of the present invention can be prepared in the form of lawns, emulsions, creams, gels, stickies, pastes, etc. by a conventional method.
(実施例)
以下、実施例、比較例の記載に基づいて本発明を詳説す
る。実施例に記載したヒト皮膚貼(J試験、にきびの治
療効果試験は下記の通りである。(Examples) Hereinafter, the present invention will be explained in detail based on the descriptions of Examples and Comparative Examples. The human skin patch (J test, acne treatment effect test described in Examples) is as follows.
ill ヒト皮膚貼付試験
被験者25名の前腕圧側部皮膚に、試料0.05gを直
径1. Q c mの円形のろ紙のついた貼付試験用絆
創膏を用いて24時間の閉塞貼付を行った。ill Human Skin Patch Test 0.05 g of sample was applied to the skin of the forearm side of 25 subjects with a diameter of 1 mm. A 24-hour occlusive application was performed using a test plaster with a Qcm circular filter paper attached.
次いで、下記第1表の判定基準に従って、絆創膏除去1
時間後、24時間後の判定を実施した0判定結果は、反
応の強い方の評価を採用し、被験者25名のうち評価が
(±)以上と判定された人の数で示した。Next, bandage removal 1 according to the criteria in Table 1 below.
The 0 judgment results obtained after 24 hours and 24 hours were based on the evaluation of the stronger reaction, and were expressed as the number of people who gave an evaluation of (±) or higher among the 25 subjects.
第 1 表
(2) にきび治療効果試験
111面かにきび症状を有する被験者の左部に対照品(
基剤のみの組成物)を、右部には実施例或いは比較例の
試験品を各々1日に朝夕2回づつ1ケ月間連続@布した
。次いで、にきび疾Φ部の7ft療効果を下記第2表の
゛−1定El 241に従って、単頭比較法により1′
す定した。判定結果は、j・I!価点の平均値で示した
。Table 1 (2) Acne treatment efficacy test 111 The control product (
On the right side, a test product of an example or a comparative example was applied twice a day in the morning and evening for a period of one month. Next, the therapeutic effect of 7ft on the acne disease Φ area was determined by the single-head comparison method according to Table 2 below, El 241.
It has been decided. The judgment result is j・I! It is shown as the average value of the value.
第 2 表
(卵黄抗体の調製〕
実施例、比較例に係るP、アクネス及びP、アクネスが
菌体外に産生ずる酸性多糖の=14製、鶏に対する免疫
、卵黄抗体の調製の例を示す。Table 2 (Preparation of egg yolk antibodies) Examples of preparation of egg yolk antibodies, immunization against chickens, and preparation of P acnes and acidic polysaccharide produced extracellularly by P acnes according to Examples and Comparative Examples are shown.
1、P、アクネスの菌体の調製
G・パブ口らの方法(ジャーナル・オブインへスティゲ
イテイブ・デルマトロジー、63巻、231−238頁
、1974年)に従って、B 111液体培地(デイフ
コ社製、51)を用いて、P。1. Preparation of P. acnes bacterial cells B 111 liquid medium (manufactured by Difco, 51 ) using P.
アクネスを嫌気的に37℃で50間培養し、遠心分離に
より菌体を培養上?Rと分離した(菌体湿重量:8.5
g)。P. acnes was cultured anaerobically at 37°C for 50 minutes, and the bacterial cells were removed from the culture by centrifugation. separated from R (wet weight of bacterial cells: 8.5
g).
2、P、アクネスが菌体外に産生ずる酸性多糖の調製
次に、0.−J、イベルセンらの方法(アーカイブス・
オブ・デルマドロジカルリサーチ、277巻、225−
229頁、1985年)によりP、アクネスが菌体外に
産生ずる酸性多糖の調製を行った。P、アクネスを培養
した上?Ht o eにエタノールを最終4度で70%
に添加し、4℃で一夜放置した。沈澱物を遠心分離によ
り集め、DNa s e、RNa s e、)リブシン
、プロナーゼで処理を行い、蛋白成分及び核酸成分を除
去し完全に可溶化した。2. Preparation of acidic polysaccharide produced by P. acnes extracellularly. - J. Iversen et al.'s method (Archives)
Of Dermatological Research, Volume 277, 225-
229, 1985), an acidic polysaccharide produced extracellularly by P. acnes was prepared. P. After culturing acne? Add ethanol to Ht oe to 70% at a final temperature of 4 degrees.
and left overnight at 4°C. The precipitate was collected by centrifugation and treated with DNase, RNase, ) ribsin, and pronase to remove protein and nucleic acid components and completely solubilize.
この分画は、更にセファロースCL −6Bカラムクロ
マトグラフィー(2,5X60cm、0.15M N
a Cl 、p II 7.2 )により、精製を行j
った。This fraction was further subjected to Sepharose CL-6B column chromatography (2.5X60cm, 0.15M N
Purification was performed using a Cl, p II 7.2).
It was.
オフタロニー法により、抗P、アクネス・ウサギ血Yi
?抗体を用いて、抗原活性を調べた結果、K a−v
= 0.23〜0.53に抗原のピークが認められたの
で、この分画を集めて濃縮、凍結乾燥し、酸性多糖を得
たく収ff1679mg)。本市の分析値は、糖含有量
: 85.4%(フェノール硫酸法)蛋白含有量: 8
.5%(ローリ−・フォーリン法)3−1.酸性多糖の
鶏に対する免疫
上記の方法で得られたP、アクネスが菌体外に産生ずる
酸性多糖を、5 m g / mβの濃度で生理食塩水
に溶解した。次に完全フロインドアジュバントと21に
混和し、完全なエマルジョンを調製した。これらのエマ
ルジョンを約1.5ケ月〜2ヶ月令の雌の鶏の左右の胸
筋に0.5 m lづつを筋肉注射した(1群10羽)
1ウ一月後に、同量の試料を再び筋肉注射した。By the ophthalony method, anti-P, acnes rabbit blood Yi
? As a result of examining antigen activity using antibodies, K a-v
Since an antigen peak was observed between = 0.23 and 0.53, these fractions were collected, concentrated, and lyophilized to obtain acidic polysaccharide (yield: 1679 mg). The analysis values for Motoichi are: Sugar content: 85.4% (phenol sulfuric acid method) Protein content: 8
.. 5% (Lori-Forin method) 3-1. Immunization of chickens with acidic polysaccharide The acidic polysaccharide produced by P. acnes extracellularly, obtained by the above method, was dissolved in physiological saline at a concentration of 5 mg/mβ. Next, the mixture was mixed with complete Freund's adjuvant to prepare a complete emulsion. These emulsions were injected intramuscularly into the left and right pectoral muscles of female chickens approximately 1.5 to 2 months old (10 birds per group).
One month later, the same amount of sample was injected intramuscularly again.
3−2.P、アクネス全菌体の鶏に対する免疫対照とし
て、予め70℃、3時間で熱処理したP、アクネス全菌
体LI−2×IO9コ/mβを上記免疫方法と同1pに
して、別の実験群の110羽に免疫した。1ケ月後に、
同量の試料を再び筋肉注射した。3-2. As a control for immunizing chickens with P. acnes whole cells, a separate experimental group was prepared using P. acnes whole cells LI-2 x IO9 co/mβ, which had been heat-treated in advance at 70°C for 3 hours, at 1 p as in the above immunization method. 110 chickens were immunized. After one month,
The same amount of sample was injected intramuscularly again.
4、抗体価の測定
免疫操作した鶏が、免疫開始前1週間、2ケ月11より
1週間、3ケ月目より1週間の期間に産生じた卯を、そ
れぞれ免疫前、2ケ月目、3ケ月目の卯として抗体値の
測定に用いた。抗体分画の調製は以下の様にして行った
。卵の卵黄を採取し、その同量の生理食塩水を加え、室
温で5分間振とうし、更に元の卵黄の2倍量のクロロホ
ルノ、を加え、30分間の振とう、攪拌を行った。得ら
れたエマルジョンを室温で30分間放置し、3000r
pmで20分間遠心分離し、上l#液を採取し、濾過滅
菌して抗体分画を得た。抗体価の推移は、常法に従って
エンザイムイムノアッセイのうちのELISAにより追
跡を行い、免疫前、2ケ月目、3ケ月目の抗体価を第3
表に示した。その結果、菌体外に産生ずる酸性多糖の方
が、抗体価の上昇性が高く、3ケ月後ではP、アクネス
全菌体の約4倍の値を示した。4. Measurement of antibody titer Rabbits produced by immunized chickens during the period of 1 week before the start of immunization, 1 week from 2nd month 11, and 1 week from 3rd month were measured at 1 week before immunization, 2 months, and 3 months, respectively. It was used as a rabbit to measure antibody levels. Antibody fractions were prepared as follows. Egg yolks were collected, the same amount of physiological saline was added thereto, and the mixture was shaken at room temperature for 5 minutes. Chlorophorno, twice the amount of the original egg yolk, was then added, followed by shaking and stirring for 30 minutes. The resulting emulsion was left at room temperature for 30 minutes and heated at 3000 r.
After centrifugation at pm for 20 minutes, the upper 1# liquid was collected and sterilized by filtration to obtain an antibody fraction. The transition of the antibody titer was tracked by ELISA of the enzyme immunoassay according to the standard method, and the antibody titer before immunization, at the 2nd month, and at the 3rd month was measured at the 3rd month.
Shown in the table. As a result, the acidic polysaccharide produced outside the bacterial cells had a higher ability to increase the antibody titer, and after three months, the value of P. acnes was approximately four times higher than that of the whole bacterial cells.
第 3 表
5、卵黄抗体の調製
次に、免疫操作開始後3ケ月目より1ケ月間の期間に鶏
が産生じた卵の卵黄を採取し、「4.抗体価の測定Jの
項で記述した通りに抗体分画を得た。Table 3. Preparation of egg yolk antibodies Next, collect the yolks of eggs produced by chickens during a period of one month from the third month after the start of immunization, and use the method described in section 4. Measurement of antibody titer J. Antibody fractions were obtained as described.
更に、この抗体分画を、硫酸アンモニウムの40%飽和
濃度により沈澱として回収し、生理食塩水に対して透析
した後、再び硫酸アンモニウムの35%飽和濃度により
沈澱として回収し、蒸留水に対して48時間透析した後
、凍結乾燥して精製された卵黄抗体を得た。得られた乾
燥抗体は、硫酸アンモニウムによる沈澱操作を行〆う前
の抗体分画の量になるように生理食塩水により再溶解し
、これを原液としてELISAにより抗体価を測定した
。その結果を第4表に示す。Furthermore, this antibody fraction was collected as a precipitate using ammonium sulfate at a 40% saturation concentration, dialyzed against physiological saline, recovered as a precipitate again using a 35% saturation concentration of ammonium sulfate, and dialyzed against distilled water for 48 hours. After dialysis, purified egg yolk antibodies were obtained by freeze-drying. The obtained dried antibody was redissolved in physiological saline to the same amount as the antibody fraction before precipitation with ammonium sulfate, and the antibody titer was measured by ELISA using this as a stock solution. The results are shown in Table 4.
第 4 表
実施例1〜7、比較例1〜4
〔にきび用ローション〕
にきび用ローション基剤に、前記(卵黄抗体の調製)の
項で得られたP、アクネスの酸性多1ノ9に対する卵黄
抗体(実施例、以下抗酸性多糖抗体と略記する) また
は])、アクネスの全菌体に対する卵黄抗体(比較例、
以下抗全閑tK体と略記する)をそれぞれ第5表に記載
の如く配合した各ム(料を調製し、試験に使用した。Table 4 Examples 1 to 7, Comparative Examples 1 to 4 [Acne lotion] In the acne lotion base, P obtained in the above section (preparation of egg yolk antibody) and egg yolk against acidic poly1-9 of acnes acnes were added. antibody (Example, hereinafter abbreviated as acid-resistant polysaccharide antibody), egg yolk antibody against whole bacterial cells of P. acnes (comparative example,
Each of the formulations containing the anti-allergic tK compound (hereinafter abbreviated as anti-allergic tK compound) as shown in Table 5 was prepared and used in the test.
ill l成 第 5 表
(2) 調製法
第5表に示すエタノール、可溶化剤、プロピレングリコ
ールを、必要に応して加熱して精製水に溶解した後、5
0℃まで冷却した。次に、卵黄抗体を添加し、組成総量
が100wr%となるように調製された残量の精製水を
加えて均一にl¥i合し、各にきび用ローションを調製
した。Table 5 (2) Preparation method After dissolving the ethanol, solubilizer, and propylene glycol shown in Table 5 in purified water by heating as necessary,
Cooled to 0°C. Next, an egg yolk antibody was added, and the remaining amount of purified water adjusted to have a total composition of 100% was added and mixed uniformly to prepare each acne lotion.
(3) 特性
実施例1〜7、比較例1〜4のにきび治療効果試験の結
果を第6表に示す。(3) Characteristics Table 6 shows the results of the acne treatment efficacy test for Examples 1 to 7 and Comparative Examples 1 to 4.
第6表に示す如く、実施例1〜7の抗酸性多糖抗体を配
合したにきび用ローションは、明らかに高いにきび治療
効果が認められた。また、ヒト皮膚貼付試験における皮
膚刺激性は認められなかった。一方、比較例1〜4の抗
全菌抗体を配合したにきび用ローションは、にきび治療
効果が低く、且つヒト皮膚貼付試験における皮膚刺激性
も高が実施例8〜14、比較例5〜8
〔にきび用スキンクリーム〕
にきび用ス;1−ンクリーム基剤に本発明に係る印面抗
体を第7表に記載の如く配合した各試料を調製し、試験
に使用した。As shown in Table 6, the acne lotions containing the anti-acid polysaccharide antibodies of Examples 1 to 7 were clearly found to have high acne treatment effects. In addition, no skin irritation was observed in human skin patch tests. On the other hand, the acne lotions containing the anti-total bacterial antibodies of Comparative Examples 1 to 4 had low acne treatment effects and high skin irritation in human skin patch tests. Skin Cream for Acne] Each sample was prepared by blending the stamped antibody according to the present invention into a skin cream base for acne as shown in Table 7, and used in the test.
(1)組成 第 表 調製法 第7表のB及びC成分を、 各々8 0℃に加熱ン容 解したものを混合した後、 0℃まで冷却した。(1) Composition No. table Preparation method The B and C components in Table 7 are 8 each Heat to 0℃ After mixing the solutions, Cooled to 0°C.
次に、卵黄抗体を添加し、撹拌しつつ冷IJ1シて30
℃まで撹拌を続けた各にきび用スキンクリームを調製し
た。Next, add the egg yolk antibody and pump it with cold IJ for 30 minutes while stirring.
Each acne skin cream was prepared by continuing to stir up to ℃.
(3) 特性
実施例8〜14、比較例5〜8のにきび治療効果試験の
結果を第8表に示す。(3) Properties Table 8 shows the results of the acne treatment efficacy test for Examples 8 to 14 and Comparative Examples 5 to 8.
第8表に示す如く、実施例8〜14の抗酸性多糖抗体を
配合したにきび用スキンクリームは、明らかに高いにき
び治療効果が認められた。また、ヒト皮膚貼付試験にお
ける皮膚!11激性は認められなかった。一方、比較例
5〜8の抗全菌抗体を配合したにきび用スキンクリーム
は、にきび治療効果が低く、且つヒト皮膚貼付試験にお
ける皮膚刺(発明の効果)
本発明のにきび用化粧料は、皮膚、刺激性が無く、にき
びの予防、治療に有効なる作用をを5し、且つ、長期間
保存しても安定であって、その商品価値は極めて高い。As shown in Table 8, the skin creams for acne containing the anti-acidic polysaccharide antibodies of Examples 8 to 14 were clearly found to have high acne treatment effects. Also, skin in human skin patch test! No 11 severity was observed. On the other hand, the skin creams for acne containing anti-total bacterial antibodies of Comparative Examples 5 to 8 have low acne treatment effects, and skin stings in human skin patch tests (effect of the invention). It is non-irritating, has effective effects in the prevention and treatment of acne, and is stable even when stored for a long period of time, so its commercial value is extremely high.
Claims (1)
が菌体外に産生する酸性多糖を免疫した鶏が産生する卵
より調製された卵黄抗体を含有することを特徴とするに
きび用化粧料。A cosmetic for acne, characterized by containing an egg yolk antibody prepared from eggs produced by chickens immunized with acidic polysaccharides produced extracellularly by Propionibacterium acnes, which is a resident bacteria of the skin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP27431388A JPH02121909A (en) | 1988-10-28 | 1988-10-28 | Cosmetic for pimple |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP27431388A JPH02121909A (en) | 1988-10-28 | 1988-10-28 | Cosmetic for pimple |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH02121909A true JPH02121909A (en) | 1990-05-09 |
Family
ID=17539908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP27431388A Pending JPH02121909A (en) | 1988-10-28 | 1988-10-28 | Cosmetic for pimple |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH02121909A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009172936A (en) * | 2008-01-28 | 2009-08-06 | Senyun Optical Corp | Method for precisely assembling metallic mold |
-
1988
- 1988-10-28 JP JP27431388A patent/JPH02121909A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009172936A (en) * | 2008-01-28 | 2009-08-06 | Senyun Optical Corp | Method for precisely assembling metallic mold |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5314873A (en) | Milk-protein hydrolyzates and compositions for use as hair and skin treating agent | |
JP2879947B2 (en) | Hair modifier | |
JP2597084B2 (en) | Cosmetic composition | |
JP2021526154A (en) | Composition for muscle relaxation | |
AU2004259030A1 (en) | Use of XMP-629 for the treatment of acne | |
CN113332160A (en) | Cosmetic composition for conditioning peritrichotic skin | |
JPH07196529A (en) | Wound-curing agent, cosmetic and hair tonic | |
JPS6219511A (en) | Cosmetic for preventing aging of skin | |
JP2003089629A (en) | Method for producing new cosmetic, new external preparation and new bathing agent | |
JPH02121910A (en) | Cosmetic for pimple | |
JP2567317B2 (en) | Hair cosmetics | |
JPH02121909A (en) | Cosmetic for pimple | |
JP2555389B2 (en) | Hair restorer | |
JP2002212100A (en) | Sphingo lipid composition for preventing and treating pimple | |
JPH03112912A (en) | Cosmetic composition | |
JP3825514B2 (en) | Whitening agent | |
JPH02121908A (en) | Cosmetic for pimple | |
JP2002316943A (en) | Anti-acne composition and cosmetic containing the same and used for acne | |
Faergemann | Epidemiology and ecology of pityriasis versicolor | |
JP2002526395A (en) | Use of Bold extract in cosmetic or dermatological products | |
JP2834278B2 (en) | Cosmetic and external preparation for skin | |
CN110680917A (en) | Preparation method and application of anti-propionibacterium acnes and staphylococcus composite IgY antigen | |
WO2007133641A1 (en) | Enhanced protection against skin injury in humans | |
JP4295841B2 (en) | Antiallergic topical agent | |
JPH01313439A (en) | Anti-acne vulgaris bacteria skin drug for external use |